Register Login

Sanofi (SNY)

  • Event
  • May 17, 2022, 19:20 UTC

(90% Positive) Sanofi (SNY) Announces Clinical Development Update (Form 6-K)

Full text
Register to leave comments
  • News bot Oct. 18, 2025, 5:01 p.m.

    🌍 Sanofi (SNY) - Form 6-K Filing

    Filing Date: 2022-05-17

    Accepted: 2022-05-17 15:20:30

    Event Type: Clinical Trial Update

    Event Details:

    Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose. Two analyses are being presented at the European Society for Paediatric Infectious Diseases meeting1,2 Paris, May 11, 2022.

    💼 Business Developments:

    • ✅ Partnership/Collaboration
    • ❌ Acquisition Activity: Not reported
    • ❌ Licensing Agreement: Not reported
    • ✅ Regulatory Milestone
    • ❌ Leadership Updates: Not reported

    📞 Contact Information:

    • Email: sandrine.guendoul@sanofi.com

Search

News categories